Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 8/20 | 0.65 |
| ▸ | GRIA4 | P48058 | 8/20 | 0.65 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289566 | 0.92 | GRIA2 (0.55) | GRIA2GRIA4ALDH1A1 | |
| SCHEMBL8288323 | 0.89 | GRIA2 (0.55) | GRIA2GRIA4PIP4K2APDE10A | |
| SCHEMBL8289421 | 0.88 | GRIA4 (0.61) | GRIA2GRIA4 | |
| SCHEMBL8289548 | 0.85 | GRIA4 (0.48) | GRIA2GRIA4 | |
| SCHEMBL8288456 | 0.84 | GRIA4 (0.56) | GRIA2GRIA4 | |
| SCHEMBL8287453 | 0.84 | GRIA4 (0.61) | GRIA2GRIA4 | |
| SCHEMBL8288325 | 0.83 | GRIA2 (0.48) | GRIA2GRIA4ALDH1A1 | |
| SCHEMBL8289530 | 0.82 | GRIA4 (0.51) | GRIA2GRIA4 | |
| SCHEMBL8289441 | 0.82 | GRIA4 (0.58) | GRIA2GRIA4 | |
| SCHEMBL8288468 | 0.82 | GRIA4 (0.50) | GRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | GRIA2 17/4885GRIA4 16/4885PIP4K2A 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.